Identifying heart issues in breast cancer patients using echocardiography
Technology Revising Ultrasound Solutions for Tomorrow - Anticancer-treatment Cardiotoxicity Identification by Echocardiography
This study is testing if a simpler heart ultrasound can help find heart problems in breast cancer patients caused by their treatment, compared to a more detailed ultrasound.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 250 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Norwegian University of Science and Technology Academic / other |
| Locations | 1 site (Trondheim) |
| Trial ID | NCT06310330 on ClinicalTrials.gov |
What this trial studies
TRUST-ACE aims to compare a simplified echocardiographic protocol that focuses on ventricular function against a comprehensive echocardiographic examination in breast cancer patients. The study will utilize a randomized design to assess the effectiveness of these approaches in identifying cancer treatment-related cardiac dysfunction (CTRCD). Additionally, it will evaluate novel tools for standardizing recordings and automating measurements like ejection fraction (EF) and global longitudinal strain (GLS) to enhance diagnostic precision in clinical practice.
Who should consider this trial
Good fit: Ideal candidates for this study are breast cancer patients who are being referred for follow-up to assess potential cardiac dysfunction related to their cancer treatment.
Not a fit: Patients who are not willing or able to provide consent will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to earlier detection and treatment of heart dysfunction in breast cancer patients, potentially preserving their cancer treatment options.
How similar studies have performed: Other studies have shown promise in using echocardiography for monitoring cardiac function in cancer patients, suggesting that this approach may be effective.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Breast cancer and referral for follow-up to identify potential CTRCD Exclusion Criteria: * Not willing or able to consent
Where this trial is running
Trondheim
- St. Olavs hospital — Trondheim, Norway (Recruiting)
Study contacts
- Principal investigator: Espen Holte, MD, PhD — St. Olavs Hospital
- Study coordinator: Espen Holte, MD. PhD
- Email: espen.holte@stolav.no
- Phone: 92243119
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.